Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result

We recently published 10 Stocks Stealing Market Spotlight. Nuvation Bio Inc. (NYSE:NUVB) is one of the best performers on Wednesday.

Nuvation rebounded by 12.05 percent on Wednesday to finish at $8.37 apiece following the stellar results of its phase 2 study for the efficacy of Safusidenib to treat of a type of brain tumor.

In an updated report on the same day, Nuvation Bio Inc. (NYSE:NUVB) said that the study met its primary endpoint, having demonstrated an objective response rate of 44.4 percent.

The study evaluated 27 patients with IDH1-mutant grade 2 gliomas who had no prior anticancer therapy except for resection or biopsy.

Side effects were also mostly mild to moderate and considered manageable.

Grade 3 or greater treatment-related adverse events occurred in five patients, while no Grade 5 events were reported.

“The results published in the journal of Neuro-Oncology demonstrate Safusidenib’s impressive response rate and prolonged progression-free survival that suggest the possibility to delay chemoradiation, potentially improving quality of life for patients,” said Nuvation Bio Inc. (NYSE:NUVB) President and CEO David Hung.

While we acknowledge the potential of NUVB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.